[The effect of the calciumantagonist dimeditiapramine on thallium-201 myocardial perfusion during exercise in patients with coronary heart disease (author's transl)].
The effect of dimeditiapramine (Ro 11-1781), a new calciumantagonist, on thallium-201 myocardial perfusion during exercise was studied in a double-blind trial with 10 patients suffering from coronary heart disease. Treatment with a single intravenous dose of 1 mg/kg body weight resulted in a significant regional thallium-201 perfusion increase in 8 out of 10 patients. These results correspond with the clinically observed decrease in exercise-induced angina and ischaemic ECG alterations. The findings indicate that dimeditiapramine might be a useful anti-anginal drug.